Xcem

X-Chem is a leading drug discovery company that pioneered the use of DNA-encoded library (DEL) technology to identify novel small molecule leads for challenging therapeutic targets. The company's proprietary platform contains billions of diverse compounds, enabling high-throughput screening against a wide range of target classes, including protein-protein interactions and GPCRs. X-Chem provides comprehensive discovery services, from initial library screening to medicinal chemistry and lead optimization, often through high-value partnerships with major pharmaceutical firms. By leveraging its massive chemical space and advanced informatics, the company accelerates the identification of high-quality drug candidates for complex diseases such as cancer and autoimmune disorders.